Soluble B7H3 level in breast cancer and its relationship with clinicopathological variables and T-cell infiltration

Okan Avci; Eyyup Çavdar; Yakup İriağaç; Kubilay Karaboyun; Aliye Çelikkol; Tuğba İlkem Kurtoğlu Özçağlaya; Meltem Öznur; Sibel Özkan Gürdal; Erdoğan Selçuk Şeber

doi:10.5114/wo.2022.113502

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2022
vol. 26

Send email

Copy url:

abstract:

Original paper

Soluble B7H3 level in breast cancer and its relationship with clinicopathological variables and T-cell infiltration

Okan Avci

¹

,

Eyyup Çavdar

¹

,

Yakup İriağaç

¹

,

Kubilay Karaboyun

¹

,

Aliye Çelikkol

¹

,

Tuğba İlkem Kurtoğlu Özçağlaya

¹

,

Meltem Öznur

¹

,

Sibel Özkan Gürdal

¹

,

Erdoğan Selçuk Şeber

¹

Tekirdağ Namık Kemal University, Turkey

Contemp Oncol (Pozn) 2022; 26 (1): 27–31

DOI: https://doi.org/10.5114/wo.2022.113502

Online publish date: 2022/02/11

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Avci O, Çavdar E, İriağaç Y, et al. Soluble B7H3 level in breast cancer and its relationship with clinicopathological variables and T-cell infiltration. Contemporary Oncology/Współczesna Onkologia. 2022;26(1):27-31. doi:10.5114/wo.2022.113502.

APA

Avci, O., Çavdar, E., İriağaç, Y., Karaboyun, K., Çelikkol, A.,  & Kurtoğlu Özçağlaya, T. et al. (2022). Soluble B7H3 level in breast cancer and its relationship with clinicopathological variables and T-cell infiltration. Contemporary Oncology/Współczesna Onkologia, 26(1), 27-31. https://doi.org/10.5114/wo.2022.113502

Chicago

Avci, Okan, Eyyup Çavdar, Yakup İriağaç, Kubilay Karaboyun, Aliye Çelikkol, Tuğba İlkem Kurtoğlu Özçağlaya,  and Meltem Öznur et al. 2022. "Soluble B7H3 level in breast cancer and its relationship with clinicopathological variables and T-cell infiltration". Contemporary Oncology/Współczesna Onkologia 26 (1): 27-31. doi:10.5114/wo.2022.113502.

Harvard

Avci, O., Çavdar, E., İriağaç, Y., Karaboyun, K., Çelikkol, A., Kurtoğlu Özçağlaya, T., Öznur, M., Özkan Gürdal, S.,  and Selçuk Şeber, E. (2022). Soluble B7H3 level in breast cancer and its relationship with clinicopathological variables and T-cell infiltration. Contemporary Oncology/Współczesna Onkologia, 26(1), pp.27-31. https://doi.org/10.5114/wo.2022.113502

MLA

Avci, Okan et al. "Soluble B7H3 level in breast cancer and its relationship with clinicopathological variables and T-cell infiltration." Contemporary Oncology/Współczesna Onkologia, vol. 26, no. 1, 2022, pp. 27-31. doi:10.5114/wo.2022.113502.

Vancouver

Avci O, Çavdar E, İriağaç Y, Karaboyun K, Çelikkol A, Kurtoğlu Özçağlaya T et al. Soluble B7H3 level in breast cancer and its relationship with clinicopathological variables and T-cell infiltration. Contemporary Oncology/Współczesna Onkologia. 2022;26(1):27-31. doi:10.5114/wo.2022.113502.

PlumX metrics:

Introduction
Although early diagnosis of breast cancer (BC) is often associated with a good prognosis, there is currently no biomarker with high sensitivity serving this purpose. B7H3, a recently identified member of the B7 family, appears to inhibit antitumor immunity. We investigated the soluble B7H3 (sB7H3) level in BC and its relationship with clinicopathological variables and stromal tumor-infiltrating lymphocytes (sTILs).

Material and methods
The study, which was designed as a cross-sectional trial between January 2020 and September 2021, included 93 BC patients, 20 patients with benign breast disease (BBD) and 14 healthy volunteers as the control group. Serum sB7H3 levels were measured using the ELISA (enzyme-linked immunosorbent assay) method and sTILs were measured by immunohistochemistry using Tru-cut biopsy materials.

Results
sB7H3 levels in BC patients were significantly higher than those in patients with BBD and healthy volunteers. Receiver operating characteristic curve analysis results showed that sB7H3 level may be a potential biomarker for distinguishing patients with BC from those with BBD (AUC: 0.807; sensitivity: 0.786; specificity: 0.706) and from healthy volunteers (AUC: 0.731; sensitivity: 0.700; specificity: 0.692).

Conclusions
To the best of our knowledge, the present study is the first to investigate the relationship between sB7H3 and disease parameters in BC. We found that sB7H3 may be a clinically practical and meaningful biomarker in differentiating BC from BBD. In order to evaluate the relationship of B7H3 with clinical variables in BC, and especially with sTILs, tissue-based studies with higher numbers of patients are needed.

keywords:

Soluble B7H3 level in breast cancer and its relationship with clinicopathological variables and T-cell infiltration

Okan Avci 1 , Eyyup Çavdar 1 , Yakup İriağaç 1 , Kubilay Karaboyun 1 , Aliye Çelikkol 1 , Tuğba İlkem Kurtoğlu Özçağlaya 1 , Meltem Öznur 1 , Sibel Özkan Gürdal 1 , Erdoğan Selçuk Şeber 1

immune checkpoint, B7 ligand family, stromal tumor-infiltrating lymphocytes

Okan Avci

¹

,

Eyyup Çavdar

¹

,

Yakup İriağaç

¹

,

Kubilay Karaboyun

¹

,

Aliye Çelikkol

¹

,

Tuğba İlkem Kurtoğlu Özçağlaya

¹

,

Meltem Öznur

¹

,

Sibel Özkan Gürdal

¹

,

Erdoğan Selçuk Şeber

¹